Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
| Autor: | Wei Shi, Weiwei Jin, Yu Hu, Linghui Xia |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Drug
Oncology medicine.medical_specialty medicine.medical_treatment Immune microenvironment media_common.quotation_subject Hematopoietic stem cell transplantation Article Oncogenic effectors Targeted therapy 03 medical and health sciences 0302 clinical medicine Immune system AML Maintenance therapy hemic and lymphatic diseases Internal medicine medicine Relapse General Pharmacology Toxicology and Pharmaceutics 030304 developmental biology media_common 0303 health sciences business.industry Myeloid leukemia medicine.disease Leukemia Metabolism surgical procedures operative 030220 oncology & carcinogenesis Allogeneic hematopoietic stem cell transplantation Surface markers business |
| Zdroj: | Acta Pharmaceutica Sinica. B |
| ISSN: | 2211-3835 |
| Popis: | Relapse remains the worst life-threatening complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML), whose prognosis has been historically dismal. Given the rapid development of genomics and immunotherapies, the interference strategies for AML recurrence have been changing these years. More and more novel targeting agents that have received the U.S. Food and Drug Administration (FDA) approval for de novo AML treatment have been administrated in the salvage or maintenance therapy of post-HSCT relapse. Targeted strategies that regulate the immune microenvironment of and optimize the graft versus leukemia (GVL) effect of immune cells are gradually improved. Such agents not only have been proven to achieve clinical benefits from a single drug, but if combined with classic therapies, can significantly improve the poor prognosis of AML patients who relapse after allo-HSCT. This review will focus on currently available and promising upcoming agents and also discuss the challenges and limitations of targeted therapies in the allogeneic hematopoietic stem cell transplantation community. Graphical abstract For recurrence after allo-HSCT, novel agents not only target oncogenic effectors, key metabolism or surface markers of leukemia cells, but also target the immune microenvironment to improve the graft versus leukemia (GVL) effect and reduce graft versus host disease (GVHD).Image 1 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|